Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03092323

Study #:
STUDY00149645

Start Date:
Jul 04, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03092323

View Complete Trial Details & Eligibility at ClinicalTrials.gov